Solana Company logo

Solana Company (HSDT)

Market Closed
3 Sep, 20:00
NASDAQ (CM) NASDAQ (CM)
$
2. 35
+0.27
+12.9808%
$
136.62M Market Cap
- P/E Ratio
- Div Yield
1.06M Volume
-16.71 Eps
$ 2.08
Previous Close
Add Transaction
Day Range
2.05 2.45
Year Range
1.19 25.5
Want to track HSDT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HSDT closed today higher at $2.35, an increase of 12.9808% from yesterday's close, completing a monthly increase of 42.4242% or $0.7. Over the past 12 months, HSDT stock lost -20.339%.
HSDT is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 8.8333%, based on the last three reports.
Solana Company has completed 5 stock splits, with the recent split occurring on Jul 01, 2025.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

HSDT Chart

People also search for

CN Healthy Food Tech Group Corp.
$ 5.51
0%
Kingstone Companies Inc.
$ 20.22
+1.864%
Gbank Financial Holdings Inc.
$ 19.95
+0.5544%
Oak Valley Bancorp
$ 34.51
+0.495%
Isabella Bank Corporation
$ 39.68
-0.4266%
Solana Company (HSDT) Q2 2026 Earnings Call Transcript

Solana Company (HSDT) Q2 2026 Earnings Call Transcript

Solana Company (HSDT) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 weeks ago
Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates

Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates

Solana Company (HSDT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $79.73 per share a year ago.

Zacks | 2 weeks ago
Solana Q2 Earnings Call Highlights

Solana Q2 Earnings Call Highlights

Solana NASDAQ: HSDT reported second-quarter 2026 revenue of $2.5 million, driven primarily by staking rewards from its digital asset treasury, as the company continued building its institutional advisory, validator infrastructure and treasury businesses across Asia-Pacific.

Marketbeat | 2 weeks ago

Solana Company Investors

Name Quantity Cost Value Profit ($) Gain (%)
ABB
Alexander Bjornager Bonde Danske Bank A/S
1 $15 $2.35 -$12.65 -84.33%
Hui Fai Tam
Hui Fai Tam Caitong International Asset Management Co. Ltd.
192 $317.08 $405.12 $88.04 27.77%
Ian Jameson
Ian Jameson American Capital Advisory, LLC
235 $3,500 $387.75 -$3,112.25 -88.92%
Highline Wealth Partners LLC
Highline Wealth Partners LLC Highline Wealth Partners LLC
500 $1,445 $825 -$620 -42.91%
GPW
Grant Private Wealth Management Inc. Grant Private Wealth Management Inc.
25,005 $61,592.13 $60,012 -$1,580.13 -2.57%

Solana Company (HSDT) FAQ

What is the stock price today?

The current price is $2.35.

On which exchange is it traded?

Solana Company is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is HSDT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 136.62M.

Has Solana Company ever had a stock split?

Solana Company had 5 splits and the recent split was on Jul 01, 2025.

Solana Company Profile

Financial Services Industry
Financials Sector
Dane Carl Andreeff CEO
NASDAQ (CM) Exchange
42328V876 CUSIP
US Country
21 Employees
4 Jan 2021 Last Dividend
1 Jul 2025 Last Split
27 Jun 2014 IPO Date

Overview

Helius Medical Technologies, Inc. stands out as a pioneering company in the realm of neurotechnology with its focus straddling the development, licensing, and procurement of innovative non-implantable technologies aimed at ameliorating symptoms attributable to neurological disorders or injuries. Founded in 2014, this firm has set its base in Newtown, Pennsylvania, marking its commitment towards delivering groundbreaking solutions to enhance neurological health and function.

Products and Services

  • Portable Neuromodulation Stimulator (PoNS™)

This avant-garde, non-surgical medical device represents Helius Medical Technologies' flagship offering. It’s specifically engineered for short-term treatment of gait deficits stemming from multiple sclerosis and balance deficits due to mild-to-moderate traumatic brain injury. A key aspect of its application involves concurrent utilization with supervised therapeutic exercises, highlighting its role as a supplementary treatment modality designed to foster improved neurological function.

Contact Information

Address: 642 Newtown Yardley Road
Phone: 215 944 6100